Kisqali Approved by FDA to Treat Hormone-Receptor-Positive, Advanced-Stage Disease

Ribociclib (Kisqali) has been approved by the U.S. Food and Drug Administration to be used in combination with an aromatase inhibitor to treat advanced-stage or metastatic, hormone-receptor-positive, HER2-negative breast cancer that hasn’t been treated with hormonal therapy yet in postmenopausal women.